BlueRock Therapeutics to Participate at Upcoming Conferences

News provided by

Nov 07, 2018, 08:00 ET

CAMBRIDGE, Mass., Nov. 7, 2018 /PRNewswire/ -- BlueRock Therapeutics, LP, an engineered cell therapy company leveraging its novel Cell+Gene platform to develop regenerative medicines for intractable diseases, today announced that the company will present at the following upcoming conferences. Presentation details are as follows:

American Heart Association Scientific Sessions 2018
Session:	Stem Cells and Their Derivatives as Therapeutics
Presentation:	Venture Capital and Industry Perspective on Cell Therapy
Date:	Monday, Nov. 12, 2018 at 8:00 a.m. EST
Location:	McCormick Place, S102bc, Chicago
For more information, please visit: https://professional.heart.org/professional/EducationMeetings/MeetingsLiveCME/ScientificSessions/UCM_316900_Scientific-Sessions.jsp

NY/NJ CEO
Presentation:	Spotlight: Building a Biotech
Date:	Wednesday, Nov. 14, 2018 at 3:00 p.m. EST
Location:	Apella by Alexandria Center, New York

Panel Presentation:	Early Stage Biotech: Strategies for Survival
Date:	Wednesday, Nov. 14, 2018 at 3:15 p.m. EST
Location:	Apella by Alexandria Center, New York
For more information, please visit: https://lifesciences.knect365.com/ny-nj-ceo/

About BlueRock Therapeutics
BlueRock Therapeutics is an engineered cell therapy company with a mission to develop regenerative medicines for intractable diseases. BlueRock's Cell+Gene platform harnesses the power of cells for new medicines across neurology, cardiology and autoimmune indications. BlueRock's cell differentiation technology recapitulates the cell's developmental biology to produce native cell therapies which are further engineered for additional function. Utilizing these cell therapies to replace damaged or degenerated tissue brings the potential to restore or regenerate lost function. BlueRock was founded in 2016 by Versant Ventures and capitalized with one of the largest-ever Series A financings in biotech history by Bayer AG and Versant. BlueRock's culture is defined by scientific innovation, highest ethical standards and an urgency to bring transformative treatments to all who would benefit. For more information, visit www.bluerocktx.com.

Media Contacts:
David Schull or Maggie Beller
Russo Partners, LLC
(646) 942-5631
[email protected]

SOURCE BlueRock Therapeutics